Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor

Journal of Surgical Research

Volumn 185, Issue 2, 2013, Pages 595-604

  Wang, Chen ^a,b   Li, Hong Yu ^c   Liu, Bin ^a,b   Huang, Sheng ^a,b   Wu, Li ^b   Li, Ying Yi ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Nude mice orthotopic model; Pim 3; VEGF

Indexed keywords

CD31 ANTIGEN; CHOLECYSTOKININ OCTAPEPTIDE; PROTEIN BAD; PROTEIN KINASE PIM 3; PROTEIN SERINE THREONINE KINASE; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ONCOPROTEIN; PIM3 PROTEIN, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MICROANGIOGRAPHY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUPERNATANT; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MICE ORTHOTOPIC MODEL; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOPHYSIOLOGY; PIM-3; TUMOR CELL LINE; VASCULARIZATION;

NUDE MICE ORTHOTOPIC MODEL; PIM-3; VEGF;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891669486     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.06.004     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277.
3. Breuer M, Slebos R, Verbeek S, et al. Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature 1989;340:61.
4. Konietzko U, Kauselmann G, Scafidi J, et al. Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. EMBO J 1999; 18:3359.
5. Feldman JD, Vician L, Crispino M, et al. KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998; 273:16535.
6. Machado HB, Liu W, Vician LJ, et al. Synaptotagmin IV overexpression inhibits depolarization-induced exocytosis in PC12 cells. J Neurosci Res 2004;76:334.
7. Li YY, Popivanova BK, Nagai Y, et al. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006;66:6741.
8. Fujii C, Nakamoto Y, Lu P, et al. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 2005;114:209.
9. Popivanova BK, Li YY, Zheng H, et al. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007;98:321.
10. Zheng HC, Tsuneyama K, Takahashi H, et al. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol 2008;134:481.
11. Aho TL, Sandholm J, Peltola KJ, et al. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43.
12. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358.
13. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182.
14. Red-Horse K, Crawford Y, Shojaei F, et al. Endothelium-microenvironment interactions in the developing embryo and in the adult. Dev Cell 2007;12:181.
15. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967.
16. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983.
17. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Network 2009;20:158.
18. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368.
19. Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109:1478.
20. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666.
21. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539.
22. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309.
23. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239.
24. Niedergethmann M, Hildenbrand R, Wostbrock B, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25:122.
25. von Marschall Z, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000;119:1358.
26. Bindukumar B, Schwartz SA, Nair MP, et al. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 2005;7:544.
27. Zippo A, De Robertis A, Bardelli M, et al. Identification of Flk-1 target genes in vasculogenesis: pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 2004;103:4536.
28. Zhang P, Wang H, Min X, et al. Pim-3 is expressed in endothelial cells and promotes vascular tube formation. J Cell Physiol 2009;220:82.
29. Koo V, Hamilton PW, Williamson K. Noninvasive in vivo imaging in small animal research. Cell Oncol 2006;28:127.
30. Schmidt GP, Wintersperger B, Graser A, et al. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest Radiol 2007; 42:449.
31. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231.
32. Büchler P, Reber HA, Ullrich A, et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2003; 134: 772.
33. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 trans-signaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456.
34. Fukuda A, Wang SC, Morris JT, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011;19:441.
35. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000.
36. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003;22:319.
37. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552.
38. Chang M, Kanwar N, Feng E, et al. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther 2010;9:2478.
39. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231.
40. Fogelman D, Jafari M, Varadhachary GR, et al. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2011;68:1431.
41. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592.
42. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004;22:1198.
43. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707.
44. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115:2618.